X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AJANTA PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AJANTA PHARMA CADILA HEALTHCARE/
AJANTA PHARMA
 
P/E (TTM) x 16.8 21.8 77.0% View Chart
P/BV x 4.0 5.1 77.7% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 CADILA HEALTHCARE   AJANTA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
AJANTA PHARMA
Mar-18
CADILA HEALTHCARE/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs5581,818 30.7%   
Low Rs3621,106 32.7%   
Sales per share (Unadj.) Rs116.3239.5 48.6%  
Earnings per share (Unadj.) Rs17.952.8 33.8%  
Cash flow per share (Unadj.) Rs23.159.5 38.9%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.4230.0 37.1%  
Shares outstanding (eoy) m1,023.7488.77 1,153.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.06.1 64.8%   
Avg P/E ratio x25.727.7 92.9%  
P/CF ratio (eoy) x19.924.6 80.9%  
Price / Book Value ratio x5.46.4 84.7%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,664129,782 362.7%   
No. of employees `00011.86.8 173.9%   
Total wages/salary Rs m18,5453,765 492.6%   
Avg. sales/employee Rs Th10,072.73,128.4 322.0%   
Avg. wages/employee Rs Th1,569.1554.0 283.2%   
Avg. net profit/employee Rs Th1,547.7689.7 224.4%   
INCOME DATA
Net Sales Rs m119,04921,258 560.0%  
Other income Rs m1,132242 468.5%   
Total revenues Rs m120,18121,499 559.0%   
Gross profit Rs m28,4756,584 432.5%  
Depreciation Rs m5,388596 904.2%   
Interest Rs m9114 22,219.5%   
Profit before tax Rs m23,3086,226 374.4%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,539 366.7%   
Profit after tax Rs m18,2924,686 390.3%  
Gross profit margin %23.931.0 77.2%  
Effective tax rate %24.224.7 97.9%   
Net profit margin %15.422.0 69.7%  
BALANCE SHEET DATA
Current assets Rs m82,00512,236 670.2%   
Current liabilities Rs m60,7203,461 1,754.7%   
Net working cap to sales %17.941.3 43.3%  
Current ratio x1.43.5 38.2%  
Inventory Days Days7360 121.5%  
Debtors Days Days9884 116.4%  
Net fixed assets Rs m83,70311,140 751.4%   
Share capital Rs m1,024177 578.9%   
"Free" reserves Rs m86,42120,237 427.0%   
Net worth Rs m87,44520,414 428.4%   
Long term debt Rs m25,55110 252,980.2%   
Total assets Rs m180,65324,486 737.8%  
Interest coverage x26.61,519.4 1.7%   
Debt to equity ratio x0.30 59,057.3%  
Sales to assets ratio x0.70.9 75.9%   
Return on assets %10.619.2 55.5%  
Return on equity %20.923.0 91.1%  
Return on capital %22.030.5 72.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68311,667 365.8%   
Fx outflow Rs m11,2421,616 695.9%   
Net fx Rs m31,44110,052 312.8%   
CASH FLOW
From Operations Rs m9,1932,854 322.1%  
From Investments Rs m-9,737-2,604 373.9%  
From Financial Activity Rs m515-2 -25,750.0%  
Net Cashflow Rs m-29248 -11.7%  

Share Holding

Indian Promoters % 74.8 73.8 101.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 1.6 535.5%  
FIIs % 5.9 7.6 77.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.0 64.7%  
Shareholders   44,069 20,968 210.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets End Lower; Metal Stocks Top Losers(Closing)

Indian share markets settled lower today led by a fall in the financial stocks after the rupee hit a record low of 70.32 per dollar.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 16, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS